Table 4.
Hepatitis C virus test results and follow-up activity. Data are numbers of participants
| Study arm | Substudy A | Substudy B | All participants | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Letter only (A1) | Letter+order (A2) | UC letter (B1) | BC letter (B2) | UC portal (B3) | BC portal (B4) | UC letter (B5) | BC letter (B6) | ||||
| Total No of participants | 813 | 829 | 947 | 950 | 4750 | 4748 | 4131 | 4135 | 21 303 | ||
| Antibody orders placed at 4 months | 181 | 829 | 213 | 197 | 904 | 827 | 745 | 715 | 4611 | ||
| Total antibody orders placed at 12 months | 333 | 829 | 404 | 401 | 1895 | 1809 | 1512 | 1466 | 8649 | ||
| Antibody screening results at 4 months | |||||||||||
| Antibody negative | 154 | 353 | 174 | 161 | 683 | 616 | 550 | 547 | 3238 | ||
| Antibody indeterminate | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 2 | ||
| Antibody positive | 2 | 4 | 1 | 1 | 7 | 5 | 15 | 10 | 45 | ||
| Completed antibody screening at 4 months | 156 | 357 | 175 | 162 | 691 | 622 | 565 | 557 | 3285 | ||
| Viral load positive | 0 | 0 | 0 | 0 | 0 | 3 | 6 | 5 | 14 | ||
| Antibody screening results at 12 months | |||||||||||
| Total antibody negative | 277 | 461 | 320 | 313 | 1409 | 1335 | 1076 | 1080 | 6271 | ||
| Total antibody indeterminate | 0 | 0 | 0 | 1 | 2 | 2 | 1 | 1 | 7 | ||
| Total antibody positive | 2 | 5 | 1 | 3 | 18 | 12 | 28 | 18 | 87 | ||
| Total completed antibody screening at 12 months | 279 | 466 | 321 | 317 | 1429 | 1349 | 1105 | 1099 | 6365 | ||
| Total completed any screening at 12 months* | 279 | 467 | 327 | 319 | 1458 | 1372 | 1115 | 1108 | 6445 | ||
| Total viral load pending | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 3 | ||
| Total viral load positive | 0 | 0 | 0 | 0 | 1 | 4 | 10 | 9 | 24 | ||
| Follow-up | |||||||||||
| Referral made | — | — | — | — | 1 | 4 | 10 | 8 | 23 | ||
| Started treatment† | — | — | — | — | 0 | 2 | 5 | 4 | 11 | ||
| SVR-12 | — | — | — | — | 0 | 1 | 3 | 1 | 5 | ||
| <12 weeks | — | — | — | — | 0 | 0 | 2 | 1 | 3 | ||
BC=behavioral content; SVR-12=sustained virologic response at 12 weeks; UC=usual care.
*
Includes testing by any means: hepatitis C virus antibody screening and those tested by hepatitis C virus viral load only (n=80).
†
Three patients unable to start treatment: two due to drug interactions, one deceased.